When buying research peptides, the certificate of analysis (COA) is the primary document linking a product to a chemical identity and purity claim. But not every COA carries equal weight, and vendors structure their disclosure practices in meaningfully different ways. Understanding where a vendor sits in the transparency hierarchy — a framework published by sources including PeptideBenchmark — helps researchers calibrate how much independent verification they are actually working with.
The Four Disclosure Tiers
PeptideBenchmark and the broader vendor-analysis community describe a rough hierarchy of COA access that spans from fully public to entirely absent. The tiers are not standardized across the industry; the names below reflect common usage rather than any single official taxonomy.
| Tier | What you see | Key limitation |
|---|---|---|
| Public / on-page | Full COA (HPLC trace, mass spec, purity %) viewable without an account, often by lot number | None specific to access — quality still depends on the testing lab |
| Gated / account | COA downloadable after registration or on request | Document may exist and be legitimate, but the friction removes casual public scrutiny |
| Third-party linked | Vendor links out to an independent lab's published result (e.g., Janoshik, Peptigrity) | Strongest signal when the lab published independently and the lot numbers match |
| None / internal only | No COA provided, or vendor claims testing without documentation | Buyer cannot verify the claim at all |
Tier placement is not a quality guarantee in either direction. A vendor in the top tier may use a captive in-house lab with limited independence; a gated vendor may share thorough documentation on request. The tier describes access, not accuracy.
What a COA Should Contain
A meaningful COA for a synthetic peptide typically reports identity confirmation (most commonly mass spectrometry, which verifies molecular weight) and purity (most commonly HPLC, which separates and quantifies components). Reputable contract manufacturers such as Bachem publish technical guidance on these analytical standards. The United States Pharmacopeia (USP) and European Medicines Agency (EMA) publish reference monographs for approved peptide drugs that describe accepted analytical methods — researchers sometimes use these as a benchmark for what rigorous testing looks like, even though research-grade vendors are not required to meet pharmaceutical standards.
A COA that reports only a single figure ("99% purity") without a named testing method, lot number, or lab identity gives a reader no way to verify or reproduce the result. Lot traceability — the ability to match a COA to a specific production batch — is the minimum that allows any external audit of the claim.
Third-Party Testing and Independent Verification
The strongest transparency signal, according to frameworks used by PeptideBenchmark and Finnrick, is an independently published third-party result where the testing lab holds the original data. Sites such as Janoshik and Peptigrity publish community-submitted samples alongside their own analytical results; when a vendor's product appears there with a matching lot number, the result exists outside the vendor's control. VialAudit aggregates and scores vendor reputation in part by tracking whether linked third-party results are consistent with vendor COA claims.
This distinction matters because a vendor-supplied COA — even a genuine one — is produced by a party with a commercial interest in the result. External replication does not eliminate all risk, but it introduces at least one independent data point.
How to Apply the Framework
For researchers evaluating a vendor, a practical starting checklist looks like this: Can you access the COA without creating an account? Does the COA name the testing lab and method? Does the lot number on the COA match the lot number on the product label? Is there any third-party result for this vendor's products on an independent platform? Vendors that score well across all four questions are, in principle, more auditable than those that do not — though none of this constitutes a safety endorsement. Research peptides are sold for research use and are not approved for human consumption; the COA framework applies to chemical identity and purity verification in a research context.
Sources
- PeptideBenchmark — vendor transparency scoring and COA tier taxonomy
- Finnrick — aggregated vendor ratings and COA access documentation
- Janoshik Analytical — independent third-party peptide testing, publicly published results
- Peptigrity — community third-party testing database
- VialAudit — vendor reputation signals including COA consistency tracking
- United States Pharmacopeia (USP) — reference analytical methods for peptide identity and purity testing